Summary The c-myc oncogene has been extensively implicated in cell proliferation, cell differentiation and programmed cell death. Aberrant expression of the c-myc gene product has been observed in a range of tumours and has also been implicated in cisplatin (cis-dichlorodiammineplatinum)-mediated chemoresistance. A solid transplantable tumour model in syngeneic DA rats was subjected to treatment with cisplatin to determine the impact of such therapy on endogenous c-myc gene expression. Serially 
The c-myc proto-oncogene, an evolutionary conserved gene found in all vertebrates, is implicated in the regulation of cell proliferation, mitogenesis, differentiation and programmed cell death (Spencer and Groudine, 1991) . Expression of c-myc is induced in proliferating cells following mitogenic stimulation (Kato et al., 1992) but is down regulated in quiescent cells following factor withdrawal (Lotem and Sachs, 1993; Hermeking and Eick, 1994) . Activation of c-myc has been associated with tumours of the breast (Watson et al., 1993) , colon , ovary (Tashiro et al., 1992) and squamous cell carcinomas (Ogunbiyi et al., 1993) . Significantly, c-myc gene activation has been correlated with poor clinical prognosis for aggressive tumours including bladder cancer (Kotake et al., 1990) and human non-small-cell lung carcinoma (Volm et al., 1993) .
Several in vitro studies of tumour cell lines suggest that elevated c-myc expression can confer resistance to cisplatin (Sklar and Prochownik, 1991; Niimi et al., 1991; Mituzani et al., 1994) . Cisplatin (cis-diamminedichloroplatinum; CDDP) is an antineoplastic agent with demonstrated clinical effectiveness against hormone-resistant prostate cancer (Yagoda and Petrylak, 1993) , ovarian carcinoma (Markman, 1993 ) and as a radiation sensitiser for advanced solid head and neck tumours (Chougule et al., 1994; Nakata et al., 1994) .
Resistance to cisplatin and other chemotherapeutic agents represents a major obstacle to effective cancer therapy as clinically significant levels of resistance emerge rapidly following treatment (Andrews and Howell, 1990; KashaniSabet et al., 1990) . Chemoresistance to cisplatin is typically generated by exposure of tumour cells in vitro to gradually increasing concentrations of the drug (Twentyman et al., 1991; Christen et al., 1993) or fractionated X-irradiation (Eichholtz-Wirth et al., 1993; Taverna et al., 1994) . Reported mechanisms for acquired cisplatin resistance include increased mRNA and enzyme activity of dTMP synthase (Scanlon and Kashani-Sabet, 1988) , induction of DNA repair enzymes (Scanlon and Kashani-Sabet, 1989; Kelland et al., 1992) , decreased drug accumulation (Gately and Howell, 1993) , increased levels of glutathione (Godwin et al., 1992) , hsp60 chaperonins (Nakata et al., 1994) and metallothioneins (Kasahara et al., 1991) . Cisplatin chemoresistance is not part of the multidrug resistance phenotype mediated by the mdrl gene (Toffoli et al., 1991) , although a number of in vitro studies have implicated roles for genes such as c-fos (Funato et al., 1992) , c-jun (Rubin et al., 1992) , c-Ha ras (Isonishi et al., 1991) and c-myc (Mizutani et al., 1994) . However, to date there is a dearth of in vivo investigations attempting to examine the relationship between cisplatin therapy and the expression of specific cellular oncogenes (Sklar and Prochownik, 1991; Osmak et al., 1993; Taverna et al., 1994) .
Antisense oligodeoxyribonucleotides are being applied to modulate the expression of specific genes (Stein and Cheng, 1993) with phosphorothioate analogues preferred over the conventional phosphodiester analogues because of their superior hybridisation affinities and resistance to degradation by nucleases (Iversen, 1991) . In vitro studies using antisense cmyc analogues have confirmed the role of c-myc in cellular proliferation (Paria et al., 1992) , signal transduction pathways (Biro et al., 1993) and differentiation (Yang and Yang, 1995) .
We have examined quantitative expression of the rat c-myc gene following cisplatin therapy using a solid tumour model serially transplantable in syngeneic DA rats. We find that the rat c-myc gene displays a sustained 2-fold elevation in expression following single-dose cisplatin chemotherapy. These findings parallel reports linking an elevation in c-myc expression with the onset of chemoresistance to cisplatin in clinically derived human tumour lines (Mizutani et al., 1994) . We have also examined the effect of phosphorothioate antisense RNAs targeted against c-myc upon cultured tumour cells and discovered that a significant reduction in cell growth rate is achievable in vitro. We hypothesise that antisense therapy directed at c-myc in combination with cisplatin may achieve therapeutic efficacies in vivo that greatly exceed those displayed by either agent in isolation. A small incision was made through the skin and a 1 mm3 piece of healthy tumour was implanted subcutaneously. Tumour growth was assessed daily using calibrated vernier calipers and expressed as the product of the minimal and maximal length of tumour axes. This method has been used extensively by this and other groups (Napoli et al., 1992; Burton et al., 1990) . The chemotherapeutic drug, cisplatin, was administered on day 10 of tumour growth to the treatment group. This point coincides with commencement of the proliferative period of tumour growth. An intravenous administration of cisplatin, equivalent to a low dose used in the clinical setting (1 mg kg-'), was delivered via the inferior vena cava and was performed during a laparotomy under general anaesthesia. In both control and treatment groups tumours were dissected free from the hind limbs after 6, 12 and 17 days growth and processed for RNA analysis. These sample points were selected from data on in vivo tumour growth kinetics ( Figure 1 ) as a pretreatment time point (day 6) and two post-treatment time points, one during the phase of tumour growth retardation (day 12) and the other well after resumption of tumour growth (day 17).
Cell Cultures Primary cell cultures were established from the in vivo passaged tumour by seeding cells into fresh RPMI-1640 medium containing 5% fetal calf serum (FCS) (Trace Biosciences) incubated at 37°C in 5% carbon dioxide. Media were supplemented with antimicrobial/antimycotic PSN antibiotics (Gibco-BRL). Cells were harvested with trypsinversene, washed three times with Hanks' balanced salt solution (Trace) before pelleting by centrifugation (3000 r.p.m.; 10 min) and processing for RNA extraction.
Antisense trials
The established in vitro cell culture was treated on day 3 of cell growth with 5 ,UM dosages (selected from preliminary studies, data not shown) of a 15-residue phosphorothioate antisense oligodeoxyribonucleotide (5'-CACGTTGAGGGG-CAT-3'). The antisense transcript was directed at the translation initiation codon and next four codons (MPLNV) of exon 2 in the rat c-myc gene (Hayashi et al., 1987) and delivered upon the fifth passage of cell culture. In addition, a scrambled sequence (mismatch) oligomer (5'-AGCGTAGGCTAGCGT-3') was employed to confirm gene specific inhibition of tumour cell growth. Cell Raw data from each group was transformed (1) and compared using linear regression analysis (Snedecor and Cochran, 1967) . Appropriate differences between means were statistically examined using a t-test (Howell, 1982) .
Results
In vivo tumour growth kinetics The effect of cisplatin was examined by comparing the tumour growth kinetics for untreated and treated animals ( Figure 1) Figure 4 . There were no significant differences in the level of c-myc expression between untreated and mismatch treatment groups (P> 0.05). c-myc transcripts were undetectable (at the sensitivities afforded by this system), following c-myc phosphorothioate antisense treatment suggesting virtually complete inhibition of c-myc expression.
Discussion
Our in vivo studies demonstrate that a single low-dose cisplatin treatment results in both tumour growth retardation and a 2-fold elevation in the level of c-myc expression. (Heikkila et al., 1987) . In addition, Myc protein is now known to modulate expression of the cyclin E gene whose product mediates the Go to S-phase transition of the cell cycle (Shichiri et al., 1993; Hanson et al., 1994) . The c-myc gene product appears to act as a transactivator, controlling genes that mediate the transition from G, to Sphase . Treatment with c-myc antisense oligomer may result in cells being held in the G, phase of the cell cycle, which has been shown to be cisplatin sensitive (Fraval and Roberts, 1978) . Indeed, recent evidence from cell culture studies favours this hypothesis. Mizutani et al. (1994) reported a synergistic cytotoxic effect for c-myc antisense in combination with cisplatin therapy for the T24 bladder tumour line and two freshly derived urinary bladder cells in culture. Interestingly, chemoresistance in these cells was completely reversed by c-myc antisense treatment.
The molecular basis for chemoresistance to platinumbased drugs is poorly understood. The rapid onset of cisplatin chemoresistance is well documented in vitro and parallels clinical observations (Andrews et al., 1990; Howell et al., 1992) . Although the basis for this resistance has been variously ascribed to several candidate genes (Funato et al., 1992; Rubin et al., 1992; Isonishi et al., 1991; Nakata et al., 1994) , no one gene has been consistently implicated, with the exception of the c-myc gene (Kashani-Sabet et al., 1990; Marazzi et al., 1991; Sklar and Prochownik, 1991; Niimi et al., 1991; Mituzani et al., 1994) . The presence of a cisplatinresponsive element within the human c-myc gene promoter was demonstrated by Spandidos et al. (1991) , who defined it within the region 290 and 350 bp upstream of the c-myc P1 cap site. Using transfected plasmids carrying the 5' c-myc linked to the chloramphenicol acetyltransferase (CAT) reporter gene, the authors were able to demonstrate that cisplatin stimulated a 9-to 11-fold elevation in activity of the CAT gene. Although our data demonstrate that relatively low doses of cisplatin can evoke a significant rise in c-myc expression, it is premature to suggest there is a direct link between cisplatin use and c-myc-modulated chemoresistance. Clearly, the mechanism for cisplatin chemoresistance remains to be investigated.
Targeted genetic disruption of c-myc gene expression represents an attractive new cancer treatment modality that in combination with classical anti-cancer therapies offers the potential for greatly enhanced therapeutic efficacies for certain cancers. In addition, chemoresistance may be reversed by gene-targeted antisense therapy directed at the c-myc gene. The use of antisense technology may have clear benefits particularly when used in conjunction with conventional chemotherapies. We are presently attempting to characterise c-myc expression in relation to the development of cisplatin chemoresistance in vivo as a foundation for evaluation of combination therapies in this tumour model.
